May 5 (Reuters) - Aldeyra Therapeutics Inc ALDX.O:
ALDEYRA THERAPEUTICS INC - NEW DRUG APPLICATION RESUBMISSION IS ANTICIPATED MID‑2025
ALDEYRA THERAPEUTICS ACHIEVES PRIMARY ENDPOINT IN PHASE 3 DRY EYE DISEASE CHAMBER TRIAL OF REPROXALAP AND PLANS NDA RESUBMISSION
Source text: ID:nBw1zhPK3a
Further company coverage: ALDX.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.